Repligen Ebit Over Time
| RGEN Stock | USD 151.94 2.78 1.80% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Repligen Performance and Repligen Correlation. Repligen |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.83) | Earnings Share (0.03) | Revenue Per Share 11.452 | Quarterly Revenue Growth 0.097 | Return On Assets 0.002 |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebit Analysis
Compare Repligen and related stocks such as Intuitive Surgical, ResMed Inc, and Merit Medical Systems Ebit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ISRG | (30.8 M) | 694.8 M | 878.1 M | 852.5 M | 544.8 M | 740 M | 945.2 M | 1.1 B | 1.2 B | 1.4 B | 767.3 M | 1.8 B | 1.2 B | 1.8 B | 1.9 B |
| RMD | 100 K | 296.4 M | 354.8 M | 417.7 M | 421.2 M | 453.7 M | 487.7 M | 578.7 M | 579.3 M | 809.7 M | 907.7 M | 982.8 M | 1.2 B | 1.3 B | 1.4 B |
| MMSI | (400 K) | 20 M | 8.1 M | (664 K) | 5 M | 1.1 M | (9 M) | (8.4 M) | (9.1 M) | (65.7 M) | (4.1 M) | 57.7 M | 89 M | 130.2 M | 136.7 M |
| ICUI | 6.8 M | 30.5 M | 61.3 M | 51.9 M | 49.2 M | 95.2 M | 113.6 M | 1.8 M | 115.8 M | 63.2 M | 99.2 M | 124.2 M | (67.3 M) | 47.8 M | 37.3 M |
| COO | 43.6 M | 288.6 M | 342.5 M | 304.5 M | 233.6 M | 321.8 M | 427.4 M | 439 M | 546.7 M | 303.3 M | 522.6 M | 530.3 M | 518.2 M | 595.9 M | 625.7 M |
| WST | 20.3 M | 49.9 M | 64.9 M | 162.4 M | 182 M | 128.6 M | 196.8 M | 228.9 M | 142.6 M | 296.6 M | 422.6 M | 772.9 M | 767.3 M | 706.8 M | 742.1 M |
| BDX | 125.1 M | 1.1 B | 757 M | 1.1 B | 645 M | 1.1 B | 763 M | 645 M | 1.8 B | 1.9 B | 2.2 B | 2.2 B | 2.1 B | 2.6 B | 2.7 B |
| HOLX | 1.7 M | 255.9 M | 284.9 M | 333.4 M | 473.9 M | 586.4 M | 500.5 M | 521.9 M | 134.4 M | 1.1 B | 2.5 B | 1.7 B | 787.2 M | 987.2 M | 1 B |
| TFX | 17.4 M | 155.9 M | 239 M | 272.3 M | 303.4 M | 323.8 M | 492.7 M | 543.1 M | 610.3 M | 659 M | 438.7 M | 635.7 M | 521.1 M | 501.6 M | 324.7 M |
| HAE | 157.3 M | 34.9 M | (4.8 M) | 47.3 M | 40.5 M | 36.3 M | 39.2 M | 56.2 M | 83.5 M | 153.9 M | 58 M | 80.8 M | 156 M | 168.4 M | 176.8 M |
| ANGO | (290 K) | 31.7 M | 37.5 M | 31.5 M | 35.8 M | 27.7 M | 35.5 M | 26.2 M | 72.9 M | (14.2 M) | (35.2 M) | (18.4 M) | (21 M) | (42 M) | (39.9 M) |
| ATR | 31.2 M | 292.7 M | 263.4 M | 296.7 M | 307.3 M | 329.2 M | 315.7 M | 337.6 M | 362.5 M | 371.7 M | 335.9 M | 351.9 M | 375.7 M | 415.2 M | 230.1 M |
| NVST | 402.8 M | 402.8 M | 402.8 M | 402.8 M | 402.8 M | 402.8 M | 402.8 M | 386.7 M | 298.4 M | 110.9 M | 42.5 M | 308.6 M | 322.3 M | 31.5 M | 29.9 M |
Repligen and related stocks such as Intuitive Surgical, ResMed Inc, and Merit Medical Systems Ebit description
My Equities
My Current Equities and Potential Positions
| Repligen | RGEN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 151.94
Check out Repligen Performance and Repligen Correlation. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Repligen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.